Price
No data yet.
Social Signal Score
Analyst Ratings
50 analystsRevenue
$1.16B+90.90%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jacob Thaysen
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 8,600
- Beta
- 1.47
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 7.95
Financials
Revenue
$1.16B+90.9%Net Income
$207.00M+60.6%EBITDA
$330.00M+65.8%Free Cash Flow
$161.00M+97.1%EPS (diluted)
$1.35+55.2%Shares Outstanding (diluted)
153.00M+3.4%Operating Expenses
$525.00MCash & Debt
$1.17BReturn of Capital
$242.00MRevenue by Segment (annual)
$4.34BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.34B | $850.00M | $5.48 |
| 2024 | $4.37B | $-1.22B | $-7.69 |
| 2023 | $4.50B | $-1.16B | $-7.35 |
| 2022 | $4.58B | $-4.40B | $-28.05 |
| 2021 | $4.53B | $762.00M | $5.08 |
| 2020 | $3.24B | $656.00M | $4.46 |
| 2019 | $3.54B | $1.00B | $6.82 |
| 2018 | $3.33B | $826.00M | $5.62 |
| 2017 | $2.75B | $726.00M | $4.97 |
| 2016 | $2.40B | $462.65M | $3.15 |
| 2015 | $2.22B | $461.56M | $3.18 |
| 2014 | $1.86B | $353.35M | $2.61 |
| 2013 | $1.42B | $125.31M | $1.00 |
| 2012 | $1.15B | $151.25M | $1.23 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ILMN's reported EPS growth of 12.2% a year over 13 years.
- EPS in 5 years
- $9.75
- Implied price
- $243.78
- Return from $273.04
- -2.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $121.20 — -55.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 21 | 25 | 29 | 33 |
|---|---|---|---|---|---|
| 2.2% | -17.6% | -14.0% | -11.0% | -8.3% | -5.9% |
| 7.2% | -13.5% | -9.8% | -6.6% | -3.8% | -1.3% |
| 12.2% | -9.5% | -5.6% | -2.2% | 0.7% | 3.3% |
| 17.2% | -5.5% | -1.4% | 2.1% | 5.2% | 7.9% |
| 22.2% | -1.4% | 2.8% | 6.5% | 9.7% | 12.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
79+12.68%Social Signal Score
Mentions (22)
- News (Marketaux)gurufocus.com·10h ago·Positive
Illumina Inc (ILMN) Shares Surge 7.6% -- What GF Score of 65 Tells Investors On October 05, 2026, Illumina <[+311 characters]
View source ↗ - News (RSS)seekingalpha·2d ago·Positive
Moderna, Illumina lead healthcare gains in September as medtech drags
View source ↗ - Newsfool.com·6d ago·Negative
Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off? Illumina (ILMN +0.04%) is building a deeper AI strategy around the biological data created by its sequencing technology. The Billion Cell Atlas, expanding drugmaker partnerships, and improving core business could create a new growth engine if Illumina can turn its scientific advantage into recurring commercial revenue.
View source ↗ - Newszacks.com·7d ago·Negative
Is the Options Market Predicting a Spike in Illumina Stock? Investors need to pay close attention to ILMN stock based on the movements in the options market lately.
View source ↗ - Newszacks.com·11d ago·Positive
Illumina Stock Surges 94.9% YTD: What's Behind the Rally? ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.
View source ↗ - News (RSS)yahoo·15d ago·Neutral
Illumina Stock Is Up 133% This Year. Here’s Where It Could Go Further.
View source ↗ - News (RSS)zerohedge·17d ago·Neutral
…weekly inflows in three months at $63.8 billion, according to BofA, citing EPFR data through Sept. 16. Index rebalances after the close tonight include Bloom Energy, Illumina and Everpure into the S&P 500 and SpaceX will get a weighting boost from a Nasdaq 100 rebalance. In poltiics, the US is expected to hold off announcing new tariffs on China and other trading partners until after next week’s summit between Presidents Xi Jinping and Donald Trump. AI is widely expected to be a central topic at…
View source ↗ - News (RSS)investing·19d ago·Neutral
Illumina stock reaches 52-week high at 231.82 USD
View source ↗ - Newszacks.com·24d ago·Positive
Illumina (ILMN) is a Top-Ranked Momentum Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·27d ago·Neutral
3 Stocks Soon Joining the S&P 500 The S&P 500 is set for another shakeup, with Bloom Energy (BE), Everpure (P), and Illumina (ILMN) all joining in the next quarterly rebalancing near the end of September.
View source ↗ - News (RSS)yahoo·28d ago·Neutral
Illumina and Everpure to Join S&P 500 in September Rebalancing: What it Means for Investors
View source ↗ - Newszacks.com·28d ago·Positive
Illumina (ILMN) Upgraded to Buy: What Does It Mean for the Stock? Illumina (ILMN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - News (RSS)yahoo·30d ago·Neutral
Bloom Energy, Illumina, Everpure Rise On S&P 500 Inclusion
View source ↗ - News (RSS)seekingalpha·31d ago·Neutral
Bloom Energy surges on inclusion to S&P 500; Illumina, Everpure also added
View source ↗ - News (RSS)investing·31d ago·Neutral
Bloom Energy, Illumina, and Everpure set to join S&P 500 in quarterly rebalance
View source ↗ - Newsprnewswire.com·31d ago·Neutral
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to coincide with the quarterly rebalance.
View source ↗ - Newszacks.com·32d ago·Neutral
Are Robots the New Normal? Bet on these ETFs to Invest in the Future Robotics is entering a new era as AI fuels humanoid adoption, with four ETFs offering diversified exposure to the sector's growth.
View source ↗ - Newszacks.com·39d ago·Neutral
Should You Add Illumina Stock to Your Portfolio Now? ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cost volatility may pressure margins.
View source ↗ - News (Marketaux)finance.yahoo.com·41d ago·Positive
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned. Illumina, the Sequencing Toll B[+299 characters]
View source ↗ - News (RSS)seekingalpha·44d ago·Positive
Illumina, Inc. Post Earnings: Buy On A Pullback
View source ↗ - Newsseekingalpha.com·45d ago·Positive
Illumina, Inc. Post Earnings: Buy On A Pullback Illumina delivered strong Q2 2026 results, beating on EPS and revenue, and raised full-year guidance for both metrics. ILMN's profitability and momentum are robust, with management emphasizing margin expansion, ongoing share buybacks, and significant cash flow. Despite a D- valuation and stagnant historical revenue, Wall Street analysts are revising growth estimates upward, anticipating a revenue breakout by 2027.
View source ↗ - Newszacks.com·54d ago·Positive
Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $1.36 per share
Typical surprise +8.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$1.31 vs $1.23beat
- Thu, Apr 30$1.15 vs $1.05beat
- Thu, Feb 5$1.35 vs $1.24beat
- Thu, Oct 30$1.34 vs $1.17beat
- Thu, Jul 31$1.19 vs $1.02beat
- Thu, May 8$0.97 vs $0.94beat
Estimates and results for ILMN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ILMN officers and directors.
- Bought
- —
- Sold
- $473.8m
0 trades
84 trades
- Meister Keith A.sold
- Meister Keith A.sold
- Meister Keith A.sold
- Meister Keith A.sold
- Meister Keith A.sold
- Meister Keith A.sold
- Meister Keith A.sold
- Meister Keith A.sold
16 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Mar 10, 2026 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (65d later)Buy$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed May 15, 2025 (44d later)Buy$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Apr 21, 2025 (20d later)Buy$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Oct 1, 2024 (32d later)Sell$15,001 - $50,000
- Michael C. Burgesshouse · TX26 · disclosed Sep 24, 2024 (21d later)Sell$15,001 - $50,000
- Thomas Keanhouse · NJ07 · disclosed May 30, 2024 (41d later)Buy$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Apr 10, 2024 (30d later)Sell$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Mar 22, 2024 (11d later)Sell$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Mar 7, 2024 (27d later)Sell$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Mar 7, 2024 (24d later)Sell$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Mar 7, 2024 (24d later)Sell$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Mar 7, 2024 (24d later)Buy$15,001 - $50,000
- Michael C. Burgesshouse · TX26 · disclosed Jan 22, 2024 (20d later)Sell$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Jan 22, 2024 (20d later)Buy$1,001 - $15,000
- Michael C. Burgesshouse · TX26 · disclosed Jan 22, 2024 (20d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.